RSS Items

Plus, Jimmy Lai faces the Hong Kong Court of Final Appeal and a big week for corporate earnings

As the health benefits of anti-obesity medicines widen, pharma companies need to rethink what they charge

Observers cite influence of index investment as non-US public companies shun London for New York

Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis

Observational study points to the potential of blockbuster drugs such as Ozempic beyond tackling obesity and diabetes

Both OZEM and THNR offer very concentrated bets on a fast-moving market

Weight loss group announces overhaul to stay relevant amid boom in demand for new medications

Activism? Pershing the thought!

Limitations on where overseas visitors can stay no longer exist yet they still risk being turned away